A controlled Phase 2 clinical trial of VCN-01
Latest Information Update: 01 Dec 2022
Price :
$35 *
At a glance
- Drugs VCN 01 (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 13 Oct 2022 According to Theriva Biologics media release, Synthetic Biologics changed it's name to Theriva Biologics
- 20 Dec 2021 New trial record
- 14 Dec 2021 According to a Synthetic Biologics media release, the company expects to provide additional details on the timing and design of these trials in the near future.